- Home
- PETZ vs BCAB Comparison
PETZ vs BCAB Comparison
Compare PETZ & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | BCAB |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PETZ | BCAB |
|---|---|---|
| Price | $1.13 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 5.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.13 |
| 52 Week High | $1.68 | $1.43 |
Technical Indicators
Market Signals| Indicator | PETZ | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 38.09 |
| Support Level | $0.94 | $0.14 |
| Resistance Level | $1.20 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 79.37 | 11.00 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.